In a European study done by Haferlach et al., 14 genes (ASXL1, CBL, ETV6, EZH2, KRAS, LAMB4, NF1, NPM1, NRAS, PRPF8, RUNX1, STAG2, TET2 and TP53) were shortlisted to stratify MDS patients into four risk groups (low, intermediate, high, and very high risk) in combination with conventional scoring or as standalone scoring tools [13]. This evidence concerns the gene EZH2 and myelodysplastic syndrome.